- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02972333
Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M
Open Label, Multi-center, Prospective Study to Investigate the Efficacy and Safety of AZD9291 in Brain Metastases From Patients With EGFR T790M Positive NSCLC Who Have Received Prior Therapy With an EGFR-TKI
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Jinming Yu, MD.PhD.
- Phone Number: 0086-531-67626919
- Email: sdyujinming@163.com
Study Contact Backup
- Name: Ligang Xing, MD.PhD.
- Phone Number: 0086-531-67626819
- Email: xinglg@medmail.com.cn
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of signed and dated written informed consent by the patient or legally acceptable representative prior to any study-specific procedures
- Metastatic (stage IV) EGFRm NSCLC, not amenable to curative surgery or radiotherapy, with confirmation of the presence of the T790M mutation.
- For patients with LM: Confirmed diagnosis of LM by positive CSF cytology. Diagnosis by MRI only is not eligible for study entry. At least one site of CNS leptomeningeal disease that can be assessed by magnetic resonance imaging (MRI) and which is suitable for repeat assessments. Measurable CNS or extracranial disease is not required.
- For patients with measurable BM but without LM: At least one measurable intracranial lesion that, if previously irradiated, has progressed or not responded to radiation therapy, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter by magnetic resonance imaging (MRI) and which is suitable for accurate repeated measurements. Measurable extracranial disease is not required.
- Prior therapy with an EGFR-TKI. Patients may have also received additional lines of treatment.
- World Health Organization (WHO) performance status 0-2 with no deterioration over the previous 2 weeks and a minimum life expectancy of 3 months.
- Adequate bone marrow reserve and organ function as demonstrated by complete blood count, biochemistry in blood and urine at baseline.
- ECG recording at baseline showing absence of any cardiac abnormality as per exclusion criterion #10.
Female patients of childbearing potential must be using adequate contraceptive measures (see Restrictions, Section 3.5), must not be breast feeding, and must have a negative pregnancy test prior to start of dosing. Otherwise, they must have evidence of nonchild bearing potential as defined below:
- Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments
- Women less than 50 years would be consider post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution
- Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation
- Male patients must be willing to use barrier contraception, i.e., condoms.
Exclusion Criteria:
Subjects should not enter the study if any of the following exclusion criteria are fulfilled:
- Previous (within 6 months) or current treatment with AZD9291
- Patients currently receiving (or unable to stop use at least 1 week prior to receiving the first dose of AZD9291) any treatment known to be potent inhibitors or inducers of cytochrome P450 (CYP) 3A4 (Appendix B)
Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, active infection* including hepatitis B, hepatitis C and human immunodeficiency virus, or significantly impaired bone marrow reserve or organ function, including hepatic and renal impairment, which in the investigator's opinion would significantly alter the risk/benefit balance.
* active infection will include any patients receiving intravenous treatment for any infection and patients with hepatitis B or C surface antigen (+) - Patients receiving oral antiviral suppressive therapy for hepatitis B or C will be permitted to enrol in the study.
- Patient with symptomatic central nervous system (CNS) metastases who is neurologically unstable or has required increasing doses of steroids to manage CNS symptoms within the 2 weeks prior to start AZD9291 administration.
- Prior whole brain radiation therapy.
- Known intracranial hemorrhage which is unrelated to tumor.
- For patients with LM and/or BM, CNS complications that require urgent neurosurgical intervention (e.g. resection or shunt placement).
- For patients with LM, inability to undergo collection of CSF.
- Past medical history of ILD, drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD
Any of the following cardiac criteria:
- Mean resting corrected QT interval (QTcF) > 470 ms using Fredericia's formula :
- Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block)
- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events
- Any unresolved toxicity from prior therapy CTCAE > grade 3 at the time of starting treatment
- History of hypersensitivity to excipients of AZD9291 or to drugs with a similar chemical structure or class to AZD9291
Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
- Absolute neutrophil count < 1.5 x 10^9/L
- Platelet count < 100 x 10^9/L
- Haemoglobin < 90 g/L
- Alanine aminotransferase > 2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases or > 5 times ULN in the presence of liver metastases
- Aspartate aminotransferase > 2.5 times ULN if no demonstrable liver metastases or > 5 times ULN in the presence of liver metastases
- Total bilirubin > 1.5 times ULN. Total bilirubin >3 times the ULN in patients with documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or in the presence of liver metastases
- Creatinine >1.5 times ULN concurrent with creatinine clearance < 50 mL/min (measured or calculated by Cockcroft and Gault equation). Confirmation of creatinine clearance is only required when creatinine is >1.5 times ULN.
- If bone metastases are present and liver function is otherwise considered adequate by the investigator then elevated ALP will not exclude the patient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: AZD9291 80mg oral each day±RT
AZD9291(80mg, QD, p.o.) was provided to patients with confirmed EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI and concurrent with brain metastasis.
Radiation therapy will be implemented according to investigator's clinical practice(A 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.).
|
All eligible patients will have access to AZD9291 regimen through the ASTRIS study as long as they continue to show clinical benefit.
Other Names:
Radiation therapy will be implemented according to investigator's clinical practice.Based on the guidelines provided for the interruption of ADZ9291 with brain radiation therapy, a 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFSo (overall progression free survival)
Time Frame: 2 years
|
To assess the efficacy of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI by PFSo
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFSe (extracranial progression-free survival)
Time Frame: 2 years
|
To further assess the efficacy of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI in pre-specified patient subgroups, e.g.
AZD9291 single regimen, AZD9291 (before or after radiotherapy) with radiotherapy etc.
|
2 years
|
PFSi (intracranial progression-free survival)
Time Frame: 2 years
|
To further assess the efficacy of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI in pre-specified patient subgroups, e.g.
AZD9291 single regimen, AZD9291 (before or after radiotherapy) with radiotherapy etc.
|
2 years
|
ORRo (overall objective response rate)
Time Frame: 2 years
|
To further assess the efficacy of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI in pre-specified patient subgroups, e.g.
AZD9291 single regimen, AZD9291 (before or after radiotherapy) with radiotherapy etc.
|
2 years
|
ORRe (extracranial objective response rate)
Time Frame: 2 years
|
To further assess the efficacy of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI in pre-specified patient subgroups, e.g.
AZD9291 single regimen, AZD9291 (before or after radiotherapy) with radiotherapy etc.
|
2 years
|
ORRi (intracranial objective response rate)
Time Frame: 2 years
|
To further assess the efficacy of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI in pre-specified patient subgroups, e.g.
AZD9291 single regimen, AZD9291 (before or after radiotherapy) with radiotherapy etc.
|
2 years
|
DCRo (overall disease control rate)
Time Frame: 2 years
|
To further assess the efficacy of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI in pre-specified patient subgroups, e.g.
AZD9291 single regimen, AZD9291 (before or after radiotherapy) with radiotherapy etc.
|
2 years
|
DCRe (extracranial disease control rate)
Time Frame: 2 years
|
To further assess the efficacy of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI in pre-specified patient subgroups, e.g.
AZD9291 single regimen, AZD9291 (before or after radiotherapy) with radiotherapy etc.
|
2 years
|
DCRi (intracranial disease control rate)
Time Frame: 2 years
|
To further assess the efficacy of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI in pre-specified patient subgroups, e.g.
AZD9291 single regimen, AZD9291 (before or after radiotherapy) with radiotherapy etc.
|
2 years
|
DoRo (overall duration of response)
Time Frame: 3 years
|
To further assess the efficacy of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI in pre-specified patient subgroups, e.g.
AZD9291 single regimen, AZD9291 (before or after radiotherapy) with radiotherapy etc.
|
3 years
|
DoRe (extracranial duration of response)
Time Frame: 2 years
|
To further assess the efficacy of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI in pre-specified patient subgroups, e.g.
AZD9291 single regimen, AZD9291 (before or after radiotherapy) with radiotherapy etc.
|
2 years
|
DoRi (intracranial duration of response)
Time Frame: 2 years
|
To further assess the efficacy of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI in pre-specified patient subgroups, e.g.
AZD9291 single regimen, AZD9291 (before or after radiotherapy) with radiotherapy etc.
|
2 years
|
OS(overall survival)
Time Frame: 3 years
|
To further assess the efficacy of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI in pre-specified patient subgroups, e.g.
AZD9291 single regimen, AZD9291 (before or after radiotherapy) with radiotherapy etc.
|
3 years
|
Adverse events/Serious adverse events
Time Frame: 2 years
|
To evaluate the safety and tolerability profile of AZD9291 and subgroups such as AZD9291 single regimen, AZD9291(before or after radiotherapy) with radiotherapy and etc. in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI.
|
2 years
|
QoL
Time Frame: 2 years
|
To assess disease-related symptoms and QoL in overall population as well as in pre-specified subgroups, e.g.
AZD9291 single regimen, AZD9291(before or after radiotherapy) with radiotherapy etc. in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI.
|
2 years
|
Cognitive function
Time Frame: 2 years
|
To assess disease-related symptoms and cognitive function in overall population as well as in pre-specified subgroups, e.g.
AZD9291 single regimen, AZD9291(before or after radiotherapy) with radiotherapy etc. in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI.
|
2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
T790M mutation positive rate
Time Frame: 2 years
|
To investigate the effect of AZD9291 on the inhibition of proof of mechanism biomarkers (to include, but not limited to EGFR T790M) in cell pellets from pre- and post-treatment CSF samples in comparison with blood samples.
|
2 years
|
Concordance of T790M status between CSF and plasma
Time Frame: 2 years
|
To investigate the effect of AZD9291 on the inhibition of proof of mechanism biomarkers (to include, but not limited to EGFR T790M) in cell pellets from pre- and post-treatment CSF samples in comparison with blood samples.
|
2 years
|
Change of imputed ctDNA concentration before and after treatment
Time Frame: 2 years
|
To investigate the effect of AZD9291 on the inhibition of proof of mechanism biomarkers (to include, but not limited to EGFR T790M) in cell pellets from pre- and post-treatment CSF samples in comparison with blood samples.
|
2 years
|
Proportion of each genetic mutation
Time Frame: 2 years
|
To investigate the effect of AZD9291 on the inhibition of proof of mechanism biomarkers (to include, but not limited to EGFR T790M) in cell pellets from pre- and post-treatment CSF samples in comparison with blood samples.
|
2 years
|
Change from baseline in glucose and protein levels
Time Frame: 2 years
|
To evaluate the changes from baseline in CSF biochemistry to support the demonstration of the anti-tumour effect of AZD9291 in addition to CSF cytology.
|
2 years
|
Change from baseline in tumor cell count
Time Frame: 2 years
|
To evaluate the changes from baseline in CSF biochemistry to support the demonstration of the anti-tumour effect of AZD9291 in addition to CSF cytology.
|
2 years
|
AZD9291 concentration level in CSF/plasma
Time Frame: 2 years
|
To explore potential relation between relevant efficacy measures, biomarkers or safety variables and plasma or CSF concentration of AZD9291 (or metabolites).
|
2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jinming Yu, MD.PhD., Shandong Cancer Hospital and Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neoplastic Processes
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Neoplasm Metastasis
- Brain Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Osimertinib
Other Study ID Numbers
- APOLLO
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonsmall Cell Lung Cancer
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedNonsmall Cell Lung Cancer Stage III | Nonsmall Cell Lung Cancer, Stage IIUnited States
-
Medical University of South CarolinaTerminatedNonsquamous Nonsmall Cell Neoplasm of Lung | Nonsmall Cell Lung Cancer Stage IIIUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteRecruitingNonsmall Cell Lung Cancer | Nonsmall Cell Lung Cancer Stage III | Unresectable Non-Small Cell Lung Carcinoma | Nonsmall Cell Lung Cancer, Stage IIUnited States
-
BeiGeneActive, not recruitingNonsmall Cell Lung Cancer, Stage IV | Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)United States, China, Korea, Republic of, France, Spain, Australia, Austria
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingNonsmall-cell Lung CancerChina
-
MIPO ClinicCompletedNonsmall-cell Lung CancerKazakhstan
-
Zealand University HospitalCompletedMetastatic Nonsmall Cell Lung CancerDenmark
-
Chang Gung Memorial HospitalCompletedAdvanced Nonsmall Cell Lung CancerTaiwan
-
University of California, DavisUnited States Department of DefenseRecruitingMetastatic Nonsmall Cell Lung CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedNonsmall Cell Lung Cancer | Nonsmall Cell Lung Cancer StageUnited States
Clinical Trials on AZD9291 80mg oral each day
-
Pharmbio Korea Co., Ltd.RecruitingColonic Diseases | Digestive System Disease | Gastrointestinal Disease | Intestinal DiseaseKorea, Republic of
-
Allama Iqbal Open University IslamabadShifa International HospitalUnknownCritical Illness | Malnutrition; ProteinPakistan
-
Vedic Lifesciences Pvt. Ltd.Recruiting
-
Antengene CorporationActive, not recruitingRelapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)China
-
Shanghai Antengene Corporation LimitedTerminatedAdvanced Solid TumorsChina
-
Florida State UniversityNOW FoodsCompletedHypertension | Obesity | Pre-hypertensionUnited States
-
AstraZenecaParexelActive, not recruitingNon-small Cell Lung CancerItaly, Spain, United States, China, Germany, Israel
-
Victoria Arija ValCarlos III Health Institute; Catalan Institute of Health; University Rovira i... and other collaboratorsCompletedAnemia Ferropenic | Risk of Hemoconcentration (Iron Levels >130g/L)Spain
-
Forest LaboratoriesCompletedGeneralized Anxiety DisorderUnited States
-
Immunic AGActive, not recruitingRelapsing-Remitting Multiple Sclerosis (RRMS)Poland, Bulgaria, Romania, Ukraine